このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

循環腫瘍DNA:TBCRC-068

2026年9月16日 更新者:Mariya Rozenblit、Yale University

ホルモン受容体陽性HER2乳がんを伴う循環腫瘍DNA誘導アジュバント療法の単一ARM第II相試験は、再発後期のリスクがある(CATE)リスクがある乳房陰性乳がん

This is a single-arm, phase II study examining elacestrant in the adjuvant treatment of patients with ER+ breast cancer who test positive for circulating tumor DNA (ctDNA) during the screening period of the trial. Our trial will proceed in three separate phases: screening, treatment, and follow-up.

調査の概要

状態

募集

条件

介入・治療

詳細な説明

This is a single-arm, phase II study examining elacestrant in the adjuvant treatment of patients with ER+ breast cancer who test positive for circulating tumor DNA (ctDNA) during the screening period of the trial. Patients with ER+ breast cancer anatomic stage IIB or III at diagnosis who are at least five years from diagnosis and have completed intended course of adjuvant endocrine therapy and are currently off endocrine therapy will be screened with ctDNA testing via the NEXT Personal MRD Detection test from Personalis. Patients who test positive for ctDNA during the screening phase will receive treatment with elacestrant for one year and continue ctDNA testing and imaging with CT scans every three months. During the follow-up period, patients in the study will continue to be ctDNA tested every six months and monitored for one year. If patients remain ctDNA positive at the completion of 12 months of study treatment, since they remain at increased risk of recurrence, they can choose to continue for an additional 12 months for a maximum of 24 months, they may also resume standard endocrine therapy or continue with standard of care surveillance during follow up.

研究の種類

介入

入学 (推定)

50

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Connecticut
      • New Haven、Connecticut、アメリカ、06510
        • 募集
        • Yale University
        • 主任研究者:
          • Mariya Rozenblit, MD
        • コンタクト:
    • District of Columbia
      • Washington D.C.、District of Columbia、アメリカ、20007
        • 募集
        • Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
        • 主任研究者:
          • Katia Khoury, MD
        • コンタクト:
    • Maryland
      • Baltimore、Maryland、アメリカ、21287
        • 募集
        • Sidney Kimmel Comprehensive Cancer Center at John Hopkins
        • コンタクト:
        • 主任研究者:
          • Jenna Canzoniero, MD
    • Massachusetts
      • Boston、Massachusetts、アメリカ、02215
        • 募集
        • Dana-Farber Cancer Institute
        • コンタクト:
        • 主任研究者:
          • Ilana M Schlam Camhi, MD MPH
    • New York
      • The Bronx、New York、アメリカ、10461
        • 募集
        • Montefiore Einstein Comprehensive Cancer Center
        • 主任研究者:
          • Jesus Anampa, MD
        • コンタクト:
    • Pennsylvania
      • Pittsburgh、Pennsylvania、アメリカ、15232
        • まだ募集していません
        • UPMC Hillman Cancer Center
        • コンタクト:
        • 主任研究者:
          • Julia Foldi, MD PhD
    • Texas
      • Houston、Texas、アメリカ、77030
        • 募集
        • The University of Texas MD Anderson Cancer Center
        • コンタクト:
        • 主任研究者:
          • Carlos H Barcenas, MD MSc

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria for Screening:

  1. Adults aged 18 years and older.
  2. Previous diagnosis of anatomic stage IIB or anatomic stage III histopathologically or cytologically confirmed ER+, HER2-, breast cancer per local laboratory as per ASCO/CAP guidelines. In the context of this trial, ER status will be considered positive if >10% of tumor cells demonstrate positive nuclear staining by immunohistochemistry, with or without progesterone receptor positivity. Patients with PR positive but ER-negative are not eligible.
  3. Participants must have been diagnosed with ER+HER2- breast cancer at least five years ago and no more than 20 years ago and must have completed adjuvant endocrine therapy.
  4. Participants must be off endocrine therapy for at least four weeks prior to screening.

Exclusion Criteria for Screening:

  1. Known current metastatic disease.

  2. Known contraindication to receiving elacestrant as per FDA package insert.

  3. Current treatment with endocrine therapy.

  4. Prior treatment with elacestrant or other investigational SERDs.

  5. Current or past invasive cancer other than breast cancer, except:

    1. Adequately treated basal or squamous cell carcinoma of the skin.
    2. Cancer survivors of previously diagnosed invasive cancer who were treated with curative intent and have no evidence of disease recurrence for five years or more and are considered low risk for future recurrence by the treating physician.
  6. Patients in the screening phase, or in the randomized trial (treatment phase), cannot start receiving therapy on another therapeutic clinical trial.

  7. Current use of strong and moderate CYP3A4 inducers/inhibitors or other prohibited concomitant medication unless an acceptable substitute is available, and the prohibited medication is discontinued at least five half-lives prior to initiation of elacestrant.

  8. Participants who are pregnant.

Inclusion Criteria for Treatment:

  1. ctDNA positivity by NEXT Personal assay.

  2. No evidence of metastatic disease on staging scans.

    a. If imaging, after review with a radiologist, is low probability for metastatic disease, patients may proceed with enrollment. Patients with suspicious but inconclusive imaging results should undergo a diagnostic biopsy; if biopsy is negative patients are eligible for enrollment. Patients with positive imaging that is conclusive of metastatic disease, or biopsy proven metastatic disease, are not eligible.

  3. At the time of informed consent signature for treatment, participants may be either postmenopausal, premenopausal, or perimenopausal.

    a. Postmenopausal status is defined by: i. Age ≥60. ii. Age <60 and amenorrhea for 12 or more months (without an alternative cause) and FSH and estradiol level within postmenopausal range per local laboratory reference.

    iii. Documentation of bilateral oophorectomy, at least one month before first dose of trial therapy.

    b. Premenopausal and perimenopausal participants must be willing to concurrently receive an LHRH agonist, and the LHRH agonist must be initiated at least three to four weeks before the start of elacestrant and are planning to continue LHRH agonist treatment during treatment with elacestrant. This is based on the current FDA approval of elacestrant in the metastatic setting which is limited to postmenopausal participants.

    c. Premenopausal or perimenopausal participants must be willing to use a highly effective method of contraception for the duration of trial treatment and for 120 days after the last dose of elacestrant OR if using barrier method of contraception must be willing to use a second form of contraception like occlusive cap with spermicidal foam / gel / film / cream / suppository.

    i. Highly effective methods of contraception are non-hormonal (cooper) intrauterine device (IUD), surgical sterilization (bilateral tubal occlusion/ligation, partner who has had a vasectomy), and sexual abstinence.

  4. ECOG performance status of 0 or 1.

  5. Patient has adequate bone marrow and organ function, as defined by the following laboratory values:

    1. Absolute neutrophil count (ANC) >1.0 x 109/L.
    2. Platelets >100 x 109/L.
    3. Hemoglobin > 8.0 g/dL.
    4. Potassium, sodium, calcium, and magnesium CTCAE v5.0 grade <1.
    5. Cockcroft-Gault based creatinine clearance >50 mL/min.
    6. ALT and AST <3 x ULN and total serum bilirubin <1.5 x ULN.
    7. Hypercholesterolemia and hypertriglyceridemia CTCAE v5.0 grade <1.

Exclusion Criteria for Treatment:

  1. Any concurrent severe and uncontrolled medical condition that would, in the sponsor-investigator's opinion, cause unacceptable safety risks or compromise compliance with the protocol including but not limited to:
  2. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral medication (uncontrolled Crohn's disease or ulcerative colitis, uncontrolled chronic nausea, vomiting, diarrhea, malabsorption, or small bowel resection).
  3. Females who are pregnant or breastfeeding.
  4. Moderate to severe liver impairment (Child-Pugh Class B and C).
  5. Hypercholesterolemia or hypertriglyceridemia > CTCAE v5.0 grade 1.
  6. Participants who are currently or are planning lactation during elacestrant treatment. Lactation during and at least one week following the last dose of elacestrant is not allowed

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Single Arm

Administration of elacestrant will follow the FDA approved dose and schedule for patients with ER+ metastatic breast cancer. Elacestrant 345 mg will be administered orally once daily for 12 cycles or until disease progression or unacceptable toxicity

Administration of elacestrant will follow the FDA approved dose and schedule for patients with ER+ metastatic breast cancer. Elacestrant 345 mg will be administered orally once daily for 12 cycles or until disease progression or unacceptable toxicity. The pills shall be administered with food (to reduce nausea and vomiting) at approximately the same time each day, and the prescription will be provided with the standard "Swallow tablets whole; do not chew, crush, or split" warning label.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Assessing Elacestrant's Impact on ctDNA Clearance in ER+HER2- Breast Cancer Patients
時間枠:Every 3 months during the treatment phase and at 3-month intervals for 12 months following the end of treatment

This study evaluates whether treatment with elacestrant improves the clearance of circulating tumor DNA (ctDNA) in patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Patients included in the study have detectable ctDNA in their plasma but show no evidence of metastatic disease on imaging, and the results will be compared against historical control data.

Every 3 months during the treatment phase and at 3-month intervals for 12 months following the end of treatment
Investigating Elacestrant's Effect on 18-Month Invasive Disease-Free Survival in ER+HER2- Breast Cancer Patients
時間枠:From the start of treatment through 18 months post-initiation of treatment

To determine whether treatment with elacestrant improves the 18-month invasive disease-free survival rate in patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. The study focuses on patients with detectable circulating tumor DNA (ctDNA) in their plasma but who have no observable metastatic disease on imaging, comparing the outcomes to historical controls.

From the start of treatment through 18 months post-initiation of treatment

二次結果の測定

結果測定
メジャーの説明
時間枠
Incidence of ctDNA Positivity in Screened ER+HER2- Breast Cancer Patients
時間枠:At baseline screening prior to treatment

To estimate the incidence rate of circulating tumor DNA (ctDNA) positivity among patients screened for the study who have estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.

At baseline screening prior to treatment
Proportion of Patients with Metastatic Disease at First Positive ctDNA Result
時間枠:From baseline screening through the first positive ctDNA detection, up to 12 months

This secondary outcome measure estimates the proportion of patients who present with clinically apparent metastatic disease (evident on imaging) at the time of their first positive ctDNA result.

From baseline screening through the first positive ctDNA detection, up to 12 months
Time to Relapse Between First Positive ctDNA and Clinical Recurrence of Metastatic Disease
時間枠:From the first positive ctDNA detection through clinical recurrence, up to 24 months

To assess the duration between the first detection of positive ctDNA and the clinical recurrence of metastatic disease, as confirmed by imaging.

From the first positive ctDNA detection through clinical recurrence, up to 24 months
Association of ctDNA Clearance with Recurrence-Free Survival and Overall Survival
時間枠:From baseline through 36 months post-treatment initiation

To evaluate whether clearance of ctDNA is associated with improved recurrence-free survival (RFS) and overall survival (OS) in ER+HER2- breast cancer patients

From baseline through 36 months post-treatment initiation
Safety, Tolerability, and Adherence to Elacestrant Treatment Protocol
時間枠:From baseline through the end of the treatment phase, up to 18 months

To assess the safety and tolerability of the elacestrant treatment, as well as patients' adherence to the treatment protocol.

From baseline through the end of the treatment phase, up to 18 months
Patient-Reported Outcomes, Fear of Recurrence and Anxiety Levels During Elacestrant Treatment
時間枠:From baseline through the end of the treatment phase, assessed every 3 months up to 18 months

To evaluate global patient-reported outcomes , fear of recurrence and anxiety levels during the elacestrant treatment phase.

From baseline through the end of the treatment phase, assessed every 3 months up to 18 months
Assessing AmDTx-MBCS' Impact on Decreasing Fear of Recurrence Scores
時間枠:Participation in the application will be offered at the first screening visit. Fear of recurrence will be assessed from baseline through the end of the treatment phase, assessed every 3 months up to 18 months.

AmDTx-MBCS is a mobile health platform that combines psychoeducation, mindfulness/meditation, and cognitive based therapy practices. Investigators will evaluate the effect of AmDTx-MBCS on global patient-reported outcomes , fear of recurrence and anxiety levels during the elacestrant treatment phase.

Participation in the application will be offered at the first screening visit. Fear of recurrence will be assessed from baseline through the end of the treatment phase, assessed every 3 months up to 18 months.
Diet and Physical Activity Levels in Breast Cancer Patients
時間枠:At the first screening visit only

To assess self reported diet and physical activity levels among screened participants via Behavioral Risk Factor Surveillance System (BRFSS) and International Physical Activity Questionnaires (IPAQ) questionnaires.

At the first screening visit only

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Mariya Rozenblit, MD、Yale University

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年9月30日

一次修了 (推定)

2027年9月1日

研究の完了 (推定)

2027年9月1日

試験登録日

最初に提出

2025年3月27日

QC基準を満たした最初の提出物

2025年4月3日

最初の投稿 (実際)

2025年4月11日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月21日

QC基準を満たした最後の更新が送信されました

2026年9月16日

最終確認日

2026年5月1日

詳しくは

本研究に関する用語

キーワード

追加の関連 MeSH 用語

その他の研究ID番号

  • 2000039112

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

はい

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する